ImmunityBio Shares Surge on Stellar Revenue Growth and Regulatory Milestones

ImmunityBio's Anktiva drives explosive 700% revenue growth to $113M in 2025, with stock surging after EU & Saudi approvals expanded its reach to 33 countries.

ImmunityBio, Inc. has delivered a financial and operational update that sent its stock soaring, fueled by explosive revenue growth for its flagship immunotherapy and a series of significant regulatory approvals that have dramatically expanded its commercial reach.

Financial Performance: Anktiva Drives Exponential Growth

The biotech company reported a net product revenue of approximately $113 million for its immunotherapy Anktiva in 2025. This figure represents a staggering year-over-year increase of roughly 700%. Unit sales growth was even more pronounced, surging about 750% to approximately 3,745 units.

The fourth quarter alone contributed $38.3 million in net product revenue. This performance marks a 431% increase compared to the same period in the prior year and a sequential quarterly growth of 20% over Q3.

On the cost side, research and development expenses rose to $63.9 million in Q4, up from $35.2 million a year earlier. This increase was driven in part by a one-time asset impairment charge of $14.0 million, alongside higher costs related to manufacturing and clinical activities. Conversely, selling, general, and administrative (SG&A) expenses decreased to $38.7 million from $41.7 million. As of December 31, 2025, ImmunityBio held $242.8 million in cash, cash equivalents, and marketable securities.

While the company's per-share loss remained negative at -$0.06 for the quarter, this result reportedly marked the third consecutive quarter of sequential improvement.

Stock Rally and Trading Activity

The market reacted strongly to the news. On Monday, the share price closed at $9.83, a gain of 12.99%. The rally accelerated on Tuesday, with shares climbing another 17.5% to close at $11.55.

The surge was accompanied by unusually high trading volumes. Approximately 86.4 million shares changed hands on Monday, followed by 82.3 million on Tuesday. These figures are substantially above the 3-month average daily volume of around 31 million shares cited by MarketBeat. According to the same source, the stock opened today at $11.55. For context, historical data shows the equity began 2026 trading near $2.02, implying it has roughly quintupled in value since the start of the year.

Global Regulatory Expansion and Strategic Partnerships

Beyond the financial results, ImmunityBio highlighted a major expansion of its regulatory footprint. Anktiva is now authorized for use in 33 countries. The company specifically noted four key jurisdictions:
* The United States (FDA approval, April 2024)
* The United Kingdom (MHRA approval, July 2025)
* Saudi Arabia (accelerated approvals for bladder cancer and metastatic non-small cell lung cancer, January 2026)
* The European Union (conditional marketing authorization from the European Commission for 27 member states plus Iceland, Norway, and Liechtenstein, February 2026)

The company stated that Saudi Arabia is the first jurisdiction to approve Anktiva for an indication beyond bladder cancer.

To support this international rollout, ImmunityBio has established commercial partnerships. In Europe, it is collaborating with Accord Healthcare to deploy over 100 sales, medical, and marketing personnel across 30 countries, and has established a subsidiary in Dublin. For the MENA region, a partnership with BioPharma & Cigalah in Saudi Arabia aims to broaden market access.

Analyst Reaction and Pipeline Outlook

In response to the developments, analysts at H.C. Wainwright raised their price target for ImmunityBio from $10 to $15 per share on Monday, citing the strong Anktiva revenue and the EU approval that expands access to 33 countries.

Looking ahead, the company is targeting a Biologics License Application submission by Q4 2026 for a randomized study in BCG-naïve patients. It is also pursuing label expansions for lung cancer and lymphopenia, with plans to engage the U.S. FDA in 2026 regarding a potential accelerated approval pathway. Concurrently, clinical programs are ongoing in glioblastoma, sepsis, non-Hodgkin lymphoma, and pancreatic cancer.